Top Industry Leaders in the Ascites Market
Latest Ascites Companies Update:
BioVie This clinical-stage biopharmaceutical company is developing pegacrisantaspase, a novel enzyme-based therapy for the treatment of malignant ascites associated with ovarian cancer. BioVie recently announced positive interim results from its Phase 2b trial, demonstrating statistically significant reductions in ascitic fluid volume and improved quality of life for patients.
Noorik Biopharmaceuticals AG: This Swiss company is focusing on developing and commercializing therapeutic solutions for fluid overload conditions, including ascites. Their lead product, pegylated human hyaluronidase (PEGPH20), is currently in Phase 3 clinical trials for the treatment of malignant ascites associated with pancreatic cancer.
BD, B. Braun, Pfizer, and Medtronic are also involved in the Ascites market, offering various products for paracentesis, drainage, and other management procedures. These companies are continuously innovating and developing new technologies to improve patient outcomes.
List of Ascites Key companies in the market
- Square Medical NV of Switzerland
- BioVie Inc. of the US
- PharmaCyte of US
- Fresenius SE & Co. KGaA of Germany
- BD of US
- GI Supply of US
- Medtronic of Ireland